John Overdeck’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$304K Buy
+566
New +$290K ﹤0.01% 4519
2023
Q2
Sell
-24,292
Closed -$5.88M 3166
2023
Q1
$5.88M Buy
24,292
+14,852
+157% +$4.05M 0.02% 826
2022
Q4
$2.74M Buy
+9,440
New +$923K 0.01% 1146
2021
Q3
Sell
-68,235
Closed -$6.65M 4513
2021
Q2
$6.65M Sell
68,235
-111,980
-62% -$13.3M 0.02% 1023
2021
Q1
$21.1M Buy
180,215
+104,104
+137% +$12.1M 0.05% 412
2020
Q4
$8.46M Buy
76,111
+9,489
+14% +$1.16M 0.02% 668
2020
Q3
$7.91M Sell
66,622
-10,720
-14% -$1.16M 0.03% 587
2020
Q2
$8.76M Buy
77,342
+59,375
+330% +$5.84M 0.04% 437
2020
Q1
$1.2M Buy
17,967
+15,717
+699% +$1.31M 0.01% 1291
2019
Q4
$205K Sell
2,250
-13,500
-86% -$1.31M ﹤0.01% 3409
2019
Q3
$1.36M Buy
+15,750
New +$1.48M ﹤0.01% 1730
2018
Q3
Sell
-13,549
Closed -$3.79M 3433
2018
Q2
$3.79M Buy
+13,549
New +$2.38M 0.01% 1173
2016
Q2
Sell
-465
Closed -$4K 3086
2016
Q1
$4K Sell
465
-9,929
-96% -$82.9K ﹤0.01% 2743
2015
Q4
$128K Buy
+10,394
New +$285K ﹤0.01% 2542
2014
Q1
Sell
-422
Closed -$77K 2153
2013
Q4
$77K Buy
+422
New +$77.3K ﹤0.01% 2101

Other funds holding MDGL

John Overdeck's MDGL Position: Q2 2026 in Review

John Overdeck opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 566 shares worth $304K. The stake represents ﹤0.01% of the portfolio and ranks #4519 among its holdings. This is a return to the name: John Overdeck previously reported a position in MDGL as recently as Q1 2023.

John Overdeck first reported a position in MDGL in Q4 2013 and has held it in 15 quarters since. The position peaked at $21.1M in Q1 2021. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • John Overdeck held 566 shares of Madrigal Pharmaceuticals worth $304K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new John Overdeck position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4519 holding.
  • John Overdeck first reported a position in Madrigal Pharmaceuticals in Q4 2013 and has held it in 15 quarters since.
  • John Overdeck's Madrigal Pharmaceuticals position peaked at $21.1M in Q1 2021.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.